- Home
- GNLX
GNLX
Genelux Corporation
as of 12-12-2025 3:59pm EST
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 202.4M | IPO Year: | 2023 |
| Target Price: | $19.75 | AVG Volume (30 days): | 195.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.99 - $8.54 | Next Earning Date: | 11-05-2025 |
| Revenue: | N/A | Revenue Growth: | -95.29% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered GNLX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Genelux Corporation (GNLX)
Head of Regulatory
Avg Cost/Share
$4.69
Shares
165
Total Value
$773.85
Owned After
68,658
SEC Form 4
Director
Avg Cost/Share
$5.00
Shares
10,000
Total Value
$50,008.00
Owned After
492,784
SEC Form 4
President and CEO
Avg Cost/Share
$5.37
Shares
4,509
Total Value
$24,210.62
Owned After
538,431
SEC Form 4
Head of Regulatory
Avg Cost/Share
$5.37
Shares
343
Total Value
$1,841.70
Owned After
68,658
SEC Form 4
Chief Technical Officer
Avg Cost/Share
$5.37
Shares
973
Total Value
$5,224.43
Owned After
156,060
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Smalling Ralph | GNLX | Head of Regulatory | Dec 5, 2025 | Sell | $4.69 | 165 | $773.85 | 68,658 | |
| Thomas John | GNLX | Director | Dec 1, 2025 | Sell | $5.00 | 10,000 | $50,008.00 | 492,784 | |
| Yu Yong | GNLX | SVP, Clinical Development | Nov 17, 2025 | Sell | $5.37 | 973 | $5,224.43 | 145,844 | |
| Zindrick Thomas | GNLX | President and CEO | Nov 17, 2025 | Sell | $5.37 | 4,509 | $24,210.62 | 538,431 | |
| Smalling Ralph | GNLX | Head of Regulatory | Nov 17, 2025 | Sell | $5.37 | 343 | $1,841.70 | 68,658 | |
| Cappello Joseph | GNLX | Chief Technical Officer | Nov 17, 2025 | Sell | $5.37 | 973 | $5,224.43 | 156,060 |
Compare GNLX vs Leading Stocks
See how GNLX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GNLX Genelux Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.